Filing Flows › CG Oncology (CGON) › Q2 2026 › vs Q1 2026
CG Oncology (CGON) Q2 2026 vs Q1 2026 (quarter over quarter)
CG Oncology's revenue rose $74K (+7%) from $1.1M in Q1 2026 to $1.2M in Q2 2026. The biggest changes: Commercial and Development Revenue +$78K (+7%); License and Collaboration Revenue −$4K (-29%).
CG Oncology, Q2 2026: revenue $1.2M, net loss $79.1M, operating cash flow −$46.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Commercial and Development Revenue | $1.1M | $1.1M | $78K | +7% |
| License and Collaboration Revenue | $10K | $14K | −$4K | -29% |
| Revenue | $1.2M | $1.1M | $74K | +7% |
| Other income, net | $7.3M | $6.2M | $1.2M | +19% |
| Net loss | $79.1M | $60.2M | $18.9M | +31% |
| Costs & expenses | $87.6M | $67.5M | $20.1M | +30% |
| Operating costs | $87.6M | $67.5M | $20.1M | +30% |
| Research & development | $54.7M | $43.7M | $10.9M | +25% |
| General & admin | $29.0M | $20.8M | $8.2M | +39% |
| Other operating costs | $3.9M | $3.0M | $963K | +33% |
| Operating cash sources | $79.1M | $60.2M | $18.9M | +31% |
| Depreciation & amortization | $850K | $841K | $9K | +1% |
| Share-based compensation | $14.3M | $6.5M | $7.9M | +121% |
| Working capital & other | $17.5M | −$4.1M | $21.5M | — |
| Cash used in operations | $46.4M | $56.9M | −$10.5M | -18% |
| Net loss absorbed | $79.1M | $60.2M | $18.9M | +31% |
Questions
How much did CG Oncology's revenue grow quarter over quarter in Q2 2026?
CG Oncology's revenue rose $74K (+7%) from $1.1M in Q1 2026 to $1.2M in Q2 2026.
What drove CG Oncology's revenue change in Q2 2026?
Commercial and Development Revenue +$78K (+7%); License and Collaboration Revenue −$4K (-29%).